Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ENPP2 | Q13822 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 2/20 | 0.45 |
| ▸ | MEN1 | O00255 | 2/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.43 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.42 |
| ▸ | PRSS2 | P07478 | 1/20 | 0.42 |
| ▸ | PRSS3 | P35030 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.42 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.42 |
| ▸ | RECQL | P46063 | 1/20 | 0.41 |
| ▸ | PRKCI | P41743 | 1/20 | 0.41 |
| ▸ | TP53 | P04637 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29899606 | 1.00 | ENPP2 (0.45) | ENPP2MAPTMEN1KMT2APRSS1 | |
| SCHEMBL1561163 | 0.83 | TDP1 (0.46) | MAPTMEN1KMT2AALDH1A1RECQL | |
| SCHEMBL16935701 | 0.82 | ENPP2 (0.48) | ENPP2MAPTPRSS1PRSS2PRSS3 | |
| SCHEMBL15564559 | 0.80 | CYP4F2 (0.46) | MAPTMEN1KMT2AALDH1A1RECQL | |
| SCHEMBL5022962 | 0.80 | SIGMAR1 (0.50) | MAPTMEN1KMT2ADDB1CRBN | |
| SCHEMBL7674710 | 0.79 | ENPP2 (0.42) | ENPP2PRSS1PRSS2PRSS3TSHR | |
| SCHEMBL21769972 | 0.79 | MKNK1 (0.43) | MAPTMEN1KMT2APRKCI | |
| SCHEMBL19121619 | 0.78 | ENPP2 (0.45) | ENPP2PRSS1PRSS2PRSS3TSHR | |
| SCHEMBL16616090 | 0.78 | ENPP2 (0.45) | ENPP2PRSS1PRSS2PRSS3TSHR | |
| SCHEMBL6258058 | 0.78 | ENPP2 (0.45) | ENPP2PRSS1PRSS2PRSS3TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 84 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250320204-A1 | 7-AZA BICYCLIC HETEROARYL DERIVATIVES AS ECTONUCLEOTIDE PYROPHOSPHATASE PHOSPHODIESTERASE 1 INHIBITORS | RIBOSCIENCE LLC (US) | 2025-10-16 | — | — | US | disclosed |
| US-20240299559-A1 | COMPOUNDS THAT MEDIATE PROTEIN DEGRADATION AND METHODS OF USE THEREOF | MONTE ROSA THERAPEUTICS AG (CH) | 2024-09-12 | — | — | US | disclosed |
| US-11780849-B2 | Imino sulfanone inhibitors of ENPP1 | VOLASTRA THERAPEUTICS, INC. (US) | 2023-10-10 | — | — | US | disclosed |
| US-11780849-B2 | Imino sulfanone inhibitors of ENPP1 | VOLASTRA THERAPEUTICS, INC. (US) | 2023-10-10 | — | — | US | disclosed |
| US-11780849-B2 | Imino sulfanone inhibitors of ENPP1 | VOLASTRA THERAPEUTICS, INC. (US) | 2023-10-10 | — | — | US | disclosed |
| WO-2023069700-A1 | COMPOUNDS THAT MEDIATE PROTEIN DEGRADATION AND METHODS OF USE THEREOF | MONTE ROSA THERAPEUTICS, INC. (US) | 2023-04-27 | — | — | WO | disclosed |
| CN-115996912-A | Iminothiolanone inhibitors of ENPP1 | 沃拉斯查疗法公司 | 2023-04-21 | — | — | CN | disclosed |
| EP-4146344-A1 | IMINO SULFANONE INHIBITORS OF ENPP1 | Volastra Therapeutics, Inc. (US) | 2023-03-15 | — | — | EP | disclosed |
| US-20230002406-A1 | IMINO SULFANONE INHIBITORS OF ENPP1 | VOLASTRA THERAPEUTICS, INC. (US) | 2023-01-05 | — | — | US | disclosed |
| US-20230002406-A1 | IMINO SULFANONE INHIBITORS OF ENPP1 | VOLASTRA THERAPEUTICS, INC. (US) | 2023-01-05 | — | — | US | disclosed |
| US-6476021-B1 | Compounds having cGMP-PDE inhibitory effect | MOCHIDA PHARMACEUTICAL CO., LTD. (JP) | 2002-11-05 | — | — | US | disclosed |
| US-6458908-B1 | A PROCESS FOR PREPARING A SULFUR-CONTAINING UNSATURATED CARBOXYLATE COMPOUND AS CLAIMED IN CLAIM 1 COMPRISING REACTING A SULFUR-CONTAINING DERIVATIVE FOR OPTICAL POLYMERS | MITSUI CHEMICALS, INC. (JP) | 2002-10-01 | — | — | US | disclosed |
| US-6432988-B1 | RHEUMATIC DISEASES, (OSTEO)ARTHRITIS, CACHEXIA, INFLAMMATORY BOWEL DISEASE, TOXIC SHOCK SYNDROME, SEPSIS, CROHN*S DISEASE, PSORIASIS AND GOUT TREATMENT | MERCKLE GMBH (DE) | 2002-08-13 | — | — | US | disclosed |
| US-6339045-B1 | CAN BE USED IN A SMALL AMOUNT, SHOWING A GOOD SELECTIVITY BETWEEN CROP AND WEED, AND CAUSING NO PHYTOTOXICITY | KUREHA KAGAKU KOGYO KABUSHIKI KAISHA (JP) | 2002-01-15 | — | — | US | disclosed |
| WO-2001085734-A1 | BENZOXAZINES FOR USE IN THE TREATMENT OF PARKINSON'S DISEASE | WARNER-LAMBERT COMPANY (US) | 2001-11-15 | — | — | WO | disclosed |
| EP-1112265-A1 | 2-ARYLALKYLTHIO -IMIDAZOLES, 2-ARYLALKENYL -THIO -IMIDAZOLES AND 2-ARYLALKINYL -THIO -IMIDAZOLES AS ANTI -INFLAMMATORY SUBSTANCES AND SUBSTANCES INHIBITING THE RELEASE OF CYTOKINE | MERCKLE GMBH (DE) | 2001-07-04 | — | — | EP | disclosed |
| EP-1057808-A2 | Sulfur-containing unsaturated carboxylate compound and its use | Mitsui Chemicals, Inc. (JP) | 2000-12-06 | — | — | EP | disclosed |
| EP-1048666-A1 | NOVEL COMPOUNDS HAVING cGMP-PDE INHIBITORY EFFECT | MOCHIDA PHARMACEUTICAL CO., LTD. (JP) | 2000-11-02 | — | — | EP | disclosed |
| WO-2000017192-A1 | 2-ARYLALKYLTHIO -IMIDAZOLES, 2-ARYLALKENYL -THIO -IMIDAZOLES AND 2-ARYLALKINYL -THIO -IMIDAZOLES AS ANTI -INFLAMMATORY SUBSTANCES AND SUBSTANCES INHIBITING THE RELEASE OF CYTOKINE | MERCKLE GMBH (DE) | 2000-03-30 | — | — | WO | disclosed |
| EP-0882715-A1 | NOVEL N-(UNSUBSTITUTED OR SUBSTITUTED)-4-SUBSTITUTED-6-(UNSUBSTITUTED OR SUBSTITUTED)PHENOXY-2-PYRIDINECARBOXAMIDES OR THIOCARBOXAMIDES, PROCESSES FOR PRODUCING THE SAME, AND HERBICIDES | KUREHA KAGAKU KOGYO KABUSHIKI KAISHA (JP) | 1998-12-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11780849-B2 | Imino sulfanone inhibitors of ENPP1 | ENPP1, ENPP3, SMPD1 | ENPP2 4/4885MAPT 4755/4885MEN1 1249/4885 |
| US-20250320204-A1 | 7-AZA BICYCLIC HETEROARYL DERIVATIVES AS ECTONUCLEOTIDE PYROPHOSPHATASE PHOSPHODIESTERASE 1 INHIBITORS | ENPP1, ENPP3, PDE7A | ENPP2 16/4885MAPT 4617/4885MEN1 1892/4885 |
| US-20230002406-A1 | IMINO SULFANONE INHIBITORS OF ENPP1 | ENPP1, ENPP3, SMPD1 | ENPP2 4/4885MAPT 4755/4885MEN1 1249/4885 |
| US-20240299559-A1 | COMPOUNDS THAT MEDIATE PROTEIN DEGRADATION AND METHODS OF USE THEREOF | CDK2, SKP2, CDK1 | ENPP2 2175/4885MAPT 3248/4885MEN1 2754/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.